Organotypic models of ovarian cancer are 3D models containing defined extracellular matrices, such as collagen and fibronectin, ovarian cancer cells with specific genetic/molecular characteristics, and one or more cancer-associated stromal cell types (fibroblasts, mesothelial cells, endothelial cells) to mimic specific metastatic niches of ovarian cancer (omentum, peritoneum, interstitial stroma) and the complex interactions within tumor tissues.
Technologies
In this section it is possible to view, also through targeted research, the technologies inserted in the PROMO-TT Database. For further information on the technologies and to contact the CNR Research Teams who developed them, it is necessary to contact the Project Manager (see the references at the bottom of each record card).
Displaying results 1 - 14 of 14
AIDD is an integrated tool and a radically new way to discovery new drugs for neurodegenerative diseases (Alzheimer’s, Epilepsy, Ageing, etc.).
Aptamers, short structured single-stranded oligonucleotides binding at high affinity to a given target protein, are selected from large combinatorial libraries through repeated cycles of incubation of the library with the target, recovery and amplification of target-bound oligonucleotides (SELEX technology, Systematic Evolution of Ligands by EXponential enrichment). SELEX can be applied to select aptamers against a known target protein or against a specific cell phenotype, without any prior knowledge of the specific target, leading to new biomarkers discovery.
The technology based on cell or tissue cultures is very useful for the production of bioactive compounds. These molecules, depending on the class they belong to, can be used in the food, pharmaceutical and cosmetic industry. In particular, the developed technology is addressed to the optimization of bioactive compounds in plant cell/tissue cultures having the biosynthetic pathway of the compound of interest.
Recently, nanoparticles and nanovesicles have been investigated as potential approaches for the treatment of neurodegenerative diseases. In particular, in the Biotech sector an increasingly deeper penetration of new treatment models and biological drugs based on cellular, subcellular and vesicle therapies is expected. The patent is based on the production of Myelin-based nanoVesicles (MyVes) produced by microfluidics, starting from myelin extracted from brain tissue. These vesicles find two major fields of applications as potential drugs or as supplements/nutraceuticals.
NANOINCICLO is a technology based on the use of nanostructured cyclodextrins (CDs) for the targeted delivery of drugs such as anticancer drugs, photodynamic drugs, anti-inflammatories, antivirals, antibacterials, nutraceuticals and metals with therapeutic and diagnostic properties. Successful CDs for the proposed technology are FDA-approved or in advanced pre-clinical investigational stage and include natural and functionalized, polymeric, and amphiphilic monomeric CDs.
Therapeutic strategies targeting cell cycle in cancer have in general failed in the clinic since the drugs have lacked the therapeutic index required to achieve a robust response against cancer cells with little or no cytotoxic effect on normal cells. NEK6 kinase, which is implicated in cell cycle control, has recently emerged as an attractive target for the development of novel anticancer drugs with enhanced therapeutic index.
With the advent of senolytic agents, capable of selectively removing senescent cells in “aged” tissues, the perception of age-associated diseases has changed from being an inevitable to a preventable phenomenon of human life. The present invention is part of this research topic with the identification of molecules with potential pro-apoptotic activity, specifically with senolytic activity. The computational approach adopted, is based on combining ligand-base and structure-based virtual screening.
Filamentous bacteriophages for size, in vivo biodistribution and easiness of engineering, are considered as natural nanoparticles. The developed technology allows the construction of bio-nanoparticles based on filamentous bacteriophages delivering proteic antigens and immunomodulating lipids. Thanks to the high content of hydrophobic residues, phage capsid proteins have high binding affinity to lipids, allowing the conjugation of immunostimulating lipids.
Plants can compete favorably with traditional expression systems (mammalian cells, yeasts or bacteria) to produce recombinant proteins/peptides of pharmaceutical/industrial/agrifood interest. This technology names “Plant Molecular Farming”. The CNR-IBBA research team offers the study of new strategies for the expression and optimization of recombinant proteins/peptides in plant-based systems (plant tissues, transgenic plants, plant cell culture). Our pipeline is based on the following modules:
The environment as well as the food production provide a number of both natural and synthetic compounds whose effects on human being as an organism have not yet been determined nor investigated.
The development of an innovative screening platform of natural marine extracts guided by biological assays represents one of the main products developed within the Antitumor Drugs and Vaccines from the SEA (ADViSE) project which aims to provide a new vision in Drug Discovery processes.
To the enterprises working in the field of nutrition/nutraceutics and drug development/repositioning, we offer the know-how and state-of-the-art instrumentation of our labs to monitor multiple relevant biological parameters at the cellular level: metabolic activity, vitality, health, but also stress and toxicity. The use of advanced imaging techniques based on fluorescent/bioluminescent probes together with the availability of time-lapse acquisitions, guarantee the cutting-edge analysis of different biological parameters over time.
Safe, efficient and specific nano-delivery systems are increasingly needed for precision and regenerative medicine and targeted therapies (e.g. anticancer and antimicrobial therapies), as well as for the cosmetic and nutraceutical sectors’ applications. Despite the appreciable success of synthetic nanovectors, like for example liposomes, their clinical and market application is hampered by some limitations: • large scale production, • low cost production • intrinsic toxicity • limited cellular uptake • limited consumer acceptance.